<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="373812">
  <stage>Registered</stage>
  <submitdate>19/10/2017</submitdate>
  <approvaldate>25/10/2017</approvaldate>
  <actrnumber>ACTRN12617001502325</actrnumber>
  <trial_identification>
    <studytitle>Apheresis of healthy subjects with induced blood stage Plasmodium vivax</studytitle>
    <scientifictitle>Apheresis of healthy subjects with induced blood stage Plasmodium vivax</scientifictitle>
    <utrn>none</utrn>
    <trialacronym>none</trialacronym>
    <secondaryid>none</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>malaria infection</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Studies of infection and infectious agents</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>This is a Phase 1 study designed to determine the safety and feasibility of using apheresis as a method for extracting all lifecycle stages of malaria parasites from the blood of healthy subjects experimentally infected with blood stage Plasmodium vivax. This study will be conducted in up to 8 subjects (8 cohorts of 1 subject each).

The apheresis procedure will involve the insertion of 2 large intravenous needles into large veins located in both antecubital fossae (elbow crease). Blood will be removed from the cannula in one arm and passed through the apheresis machine and then returned to the participant through the cannula in the other arm. The Spectra Optia Apheresis System acts by separating blood into its various components by density. At the same time as the blood is removed, an anticoagulant (citrate) will be infused into your other arm meaning the total blood volume will remain the same. The whole apheresis procedure will take approximately 2-4 hours.

Subjects will be inoculated intravenously on Day 0 with approximately 1100 viable P. vivax HMPBS02-Pv parasite-infected erythrocytes. On an outpatient basis, subjects will be monitored daily via phone and then will attend the clinical unit daily from 4 days post-inoculation for blood sampling to measure parasitaemia via quantitative polymerase chain reaction (qPCR) targeting the P. vivax 18S rRNA gene (referred to as malaria 18S qPCR), to monitor symptoms and signs of malaria, and to record adverse events. The threshold for the commencement of apheresis and subsequent antimalarial rescue treatment with artemether/lumefantrine will occur when parasitaemia is greater than 20,000 parasites/mL or the Malaria Clinical Score is greater than 6 (within 24 hours of notification) or at the Investigators discretion. On the day that this threshold is reached (expected to occur on Day 10), the subject will be admitted to the clinical unit for initial safety assessments before undergoing apheresis whilst being supervised by the apheresis specialist nurse. The subject will then be administered the first dose of artemether/lumefantrine and will remain confined within the clinical unit for 72 hours to monitor for safety and tolerability of apheresis and rescue therapy, and to ensure adequate clinical and parasitological response to treatment. A course of artemether/lumefantrine treatment consists of 20 mg artemether/120 mg lumefantrine oral tablets with 6 doses of 4 tablets administered over a period of 60 hours. 

In the unlikely event that artemether/lumefantrine fails to clear parasitaemia, subjects will be treated with chloroquine phosphate. Chloroquine phosphate 250 mg oral tablets will be administered as an initial dose of 4 tablets, followed by a dose of 2 tablets each at 6, 24 and 48 hours (i.e. a total dose of 2.5 g chloroquine phosphate). If oral administration of either artemether/lumefantrine or chloroquine phosphate is not possible (e.g. the subject is vomiting), the subject will receive intravenous treatment with artesunate. This would be done at the recommended dose regime of 2.4 mg/kg at approximately 0, 12, 24, 48 hours and then daily for up to 7 days or until able to take oral drugs. After discharge from the clinical unit, subjects will be followed up on an out-patient basis for monitoring of safety and parasite clearance. Follow-up for safety assessments will be performed on Day 28 plus or minus 3, Day 56 plus or minus 7 (phone call only), and Day 90 plus or minus 7(End of Study).

</interventions>
    <comparator>No Control Group</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Drugs</interventioncode>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Primary outcome
The primary objectives will be assessed by adverse events (AE) recording, safety laboratory parameters, vital signs recording, electrocardiograms (ECGs), physical examination findings and
Malaria Clinical Score recording.
</outcome>
      <timepoint>Time-point 1
Adverse event recording: at all clinic visits from parasite inoculation to Day 90 plus or minus 7 (End of Study).

Safety laboratory parameters (biochemistry, haematology, urinalysis):
biochemistry and haematology testing done at screening, Day -3 to Day -1 eligibility confirmation visit (if required), Day 9, on clinic admission prior to apheresis, post-apheresis pre-artemether/lumefantrine treatment, prior to exit of confinement, prior to chloroquine phosphate treatment (if required), post-chloroquine phosphate treatment, during out-patient monitoring at the Investigators discretion, and Day 28 plus or minus 3. Urinalysis will be done at screening, Day -3 to Day -1 eligibility confirmation visit (if required), on clinic admission prior to apheresis, during out-patient monitoring at the Investigators discretion, and Day 28 plus or minus 3.

Vital signs recording: screening and at all clinic visits from parasite inoculation to Day 90 plus or minus 7.

ECGs: screening, prior to parasite inoculation on Day 0, post-apheresis pre-artemether/lumefantrine treatment, prior to exit of confinement, and Day 28 plus or minus 3.

Malaria Clinical Score recording: Day 0, Day 4 until artemether/lumefantrine treatment, on clinic admission prior to apheresis, during confinement, and during out-patient monitoring at the Investigators discretion.
</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>The feasibility of apheresis as a method of extracting and concentrating all stages of malaria parasites will be determined by qPCR, qRT-PCR, microscopy, and flow cytometry on blood products extracted using apheresis, and expressed as a percentage of baseline parasitaemia (pre-apheresis).</outcome>
      <timepoint>Pre-apheresis, apheresis samples, post-apheresis pre-artemether/lumefantrine treatment. </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The success of cryopreservation of gametocytes will be determined by measuring their infectivity to mosquitoes using a membrane feeding assay, reported as prevalence of infection (percentage of oocyst positive mosquitoes). The success of cryopreservation of asexual parasites will be determined based on their viability tested using in vitro reinvasion
assay.
</outcome>
      <timepoint>Apheresis samples before and after cryopreservation.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1.	Adult (male and non-pregnant, non-lactating female) subjects between 18 and 55 years of age, inclusive who do not live alone (from Day 0 until at least the end of the anti-malarial drug treatment) and will be contactable and available for the duration of the trial and up to 2 weeks following end of study visit. 
2.	Body mass index between 18.0 and 32.0 kg/m2, inclusive and a minimum body weight of 50 kg.
3.	Certified as healthy by a comprehensive clinical assessment (detailed medical history and complete physical examination).
4.	Normal standard 12-lead electrocardiogram (ECG) after 5 minutes resting in supine position.
5.	Laboratory parameters within the normal range, unless the Investigator considers an abnormality to be clinically irrelevant for healthy subjects enrolled in this study.
6.	As there is the risk of adverse effects with artemether/lumefantrine and chloroquine in pregnancy, it is important that any subjects involved in this study do not get pregnant.
7.	All subjects must be Duffy Blood group positive and have blood type O. Female subjects of childbearing potential should be blood group Rh positive. 
</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>55</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>1.	Any history of malaria or participation in a previous malaria challenge study.
2.	Must not have travelled to or lived (greater than 2 weeks) in a malaria-endemic region during the past 12 months or planned travel to a malaria-endemic region during the course of the study.
3.	Has evidence of increased cardiovascular disease risk.
4.	History of splenectomy.
5.	Presence or history of drug hypersensitivity, or allergic disease diagnosed by an allergist/immunologist and/or treated by a physician for allergy or history of a severe allergic reaction, anaphylaxis or convulsions following any vaccination or infusion.
6.	Presence of current or suspected serious chronic diseases such as cardiac or autoimmune disease (HIV or other immuno-deficiencies), insulin-dependent and non-insulin dependent diabetes, progressive neurological disease, severe malnutrition, acute or progressive hepatic disease, acute or progressive renal disease, porphyria, psoriasis, rheumatoid arthritis, asthma, epilepsy, or obsessive compulsive disorder.
7.	Frequent headaches and/or migraines, recurrent nausea, and/or vomiting (more than twice a month).
8.	Presence of acute infectious disease or fever (e.g., sub-lingual temperature greater than or equal to 38.5 Degrees Celcius) within the 5 days prior to inoculation with malaria parasites.
9.	Evidence of acute illness within the 4 weeks prior to screening that the Investigator deems may compromise participant safety.
10.	Participant has a clinically significant disease or any condition or disease that might affect drug absorption, distribution or excretion (e.g. gastrectomy, diarrhoea).
11.	Participation in any investigational product study within the 12 weeks preceding the study.
12.	Blood donation, any volume, within 1 month before inclusion, or participation in any research study involving blood sampling (more than 450 mL/unit of blood), or blood donation to the Australian Red Cross Blood Service (Blood Service) or other blood bank during the 8 weeks preceding the treatment drug dose in the study.
13.	Participant who has ever received a blood transfusion.
14.	Any vaccination within the last 28 days.
15.	Any recent ( less than 6 weeks) or current systemic therapy with an antibiotic or drug with potential anti-malarial activity (i.e. chloroquine, piperaquine, benzodiazepine, flunarizine, fluoxetine, tetracycline, azithromycin, clindamycin, doxycycline etc.).
16.	Cardiac/QT risk.
17.	Known hypersensitivity to artemether/lumefantrine or chloroquine or any of thier excipients, or 4-aminoquinolines, artemether or other artemisinin derivatives, lumefantrine, piperaquine.
</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety</endpoint>
    <statisticalmethods>This study is a exploratory study to investigate the safety and plausibility of apheresis as a method for extracting and concentrating parasites from healthy subjects experimentally infected with blood stage P. vivax. Therefore, statistical considerations regarding sample size do not apply. We estimate that a total of up to 8 subjects inoculated in a sequential manner will be sufficient to meet the objectives of this study. Approximately 4 weeks after the inoculation of each subject an assessment of all data collected will be performed. If it is deemed by the Principal Investigator that there is no need to proceed further as all objectives of the study have been met, the study may be considered complete with fewer than 8 subjects enrolled. 

No formal statistical analysis plan will be generated. Continuous data will be summarised using descriptive statistics (mean and standard deviation, or median and interquartile range). Categorical data will be presented using N and percentage (using the number of subjects without missing data in the calculation).
</statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>13/11/2017</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate>31/12/2018</anticipatedenddate>
    <actualenddate />
    <samplesize>8</samplesize>
    <actualsamplesize />
    <currentsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>19/01/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD</recruitmentstate>
    <hospital>Q-Pharm Pty - Clive Berghofer Research Centre (CBCRC) - Herston</hospital>
    <postcode>4007 - Herston</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Charities/Societies/Foundations</primarysponsortype>
    <primarysponsorname>QIMR Berghofer Medical Research Institute</primarysponsorname>
    <primarysponsoraddress>300 Herston Road, Herston, Queensland 4006</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>QIMR Berghofer Medical Research Institute</fundingname>
      <fundingaddress>300 Herston Road, Herston, Queensland 4006</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Hospital</othercollaboratortype>
      <othercollaboratorname>Associate Professor Glen Kennedy Royal Brisbane and Womenâ€™s Hospital, Brisbane</othercollaboratorname>
      <othercollaboratoraddress>Metro North HHS
Herston QLD 4029</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study will investigate the safety of carrying out an apheresis procedure on healthy participants infected with Plasmodium vivax malaria parasites. Apheresis is the name of a process, which involves the removal of all or, as is the case in this study, part of one of the components that makes up a persons blood. We want to see whether apheresis can be used as a way of collecting all the stages of the P. vivax parasite found in the blood. We hypothesise that the apheresis procedure is safe in healthy participants infected with P. vivax and that apheresis can be used to extract and concentrate all stages of P. vivax parasites at numbers greater than can be attained by simple blood draws. It is hoped that information gained from this study may lead to the development of interventions that effectively treat and prevent malaria and its spread in areas of the world where this parasite continues to cause significant sickness and death.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>QIMR Berghofer Human Research Ethics Committee</ethicname>
      <ethicaddress>300 Herston Road, Herston, QLD 4006 </ethicaddress>
      <ethicapprovaldate>22/09/2017</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>James McCarthy</name>
      <address>Q-Pharm Pty Limited
Level 5, Clive Berghofer Cancer Research Centre (CBCRC)
300C Herston Rd
Herston QLD 4006
</address>
      <phone>+61 7 3845 3636</phone>
      <fax>+61 7 3845 3637</fax>
      <email>j.mccarthy@uq.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>James McCarthy</name>
      <address>Q-Pharm Pty Limited
Level 5, Clive Berghofer Cancer Research Centre (CBCRC)
300C Herston Rd
Herston QLD 4006
</address>
      <phone>+61 7 3845 3636</phone>
      <fax>+61 7 3845 3637</fax>
      <email>j.mccarthy@uq.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>James McCarthy</name>
      <address>Q-Pharm Pty Limited
Level 5, Clive Berghofer Cancer Research Centre (CBCRC)
300C Herston Rd
Herston QLD 4006

</address>
      <phone>+61 7 3845 3636</phone>
      <fax>+61 7 3845 3637</fax>
      <email>j.mccarthy@uq.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Mrs</title>
      <name>Sashika Naidoo</name>
      <address>QIMR Berghofer Medical Research Institute
300 Herston Rd
Herston QLD 4006
</address>
      <phone>+61 7 3362 0433</phone>
      <fax>+61 7 3362 0109</fax>
      <email>sashika.naidoo@qimrberghofer.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>